IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application: **Deborah Ann Law** *et al.*   )

)

Application No. **09/673,302**   )   Group Art Unit: **1632**

)

Filed: **March 23, 2001**   )   Examiner: **Thaian N. Ton**

)

For: **Transgenic Mammals Expressing Mutant**)

      GP IIIa   )

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL FORM

1.   Transmitted herewith is a <u>Sequence Listing</u> in response to the Office Communication dated March 6, 2002 (Paper No. 12).

2.   <u>Extension of Time</u>: The proceedings herein are for a patent application and the provisions of 37 C.F.R. § 1.136(a) apply. Applicants do not believe an extension of time is required with the filing of this paper. The due date for reply is April 6, 2002. Since April 6, 2002 is a Saturday, the reply is timely filed the next business day, Monday, April 8, 2002. However, this conditional petition is being made to provide for the possibility that Applicants have inadvertently overlooked the need for a petition and fee for an extension of time. The Commissioner is hereby authorized to charge any additional fees which may be required, including fees due under 37 C.F.R. § 1.16 and § 1.17, or credit any overpayment to Deposit Account 50-0310.

3.   <u>Additional Papers Filed</u>:
    (i)   Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures
    (ii)   Copy of Raw Sequence Listing Error Report
    (iii)   Statement Accompanying Sequence Listing
    (iv)   Sequence Listing – 9 pages
    (v)   Computer Diskette with electronic copy of Sequence Listing
    (vi)   Information Disclosure Statement Under 37 C.F.R. § 1.97(c)
    (vii)   Form PTO-1449
    (viii) Copies of 6 documents and international search report

4.   <u>Fee Payment</u>: The Commissioner is hereby authorized to charge **$180.00** to Deposit Account No. 50-0310 for payment of the Information Disclosure Statement fee.

5. <u>Constructive Petition</u>: **Except** for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. § 1.16 and § 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Respectfully submitted
Morgan, Lewis & Bockius LLP

Dated: **April 8, 2002**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Suzanne E. Ziska, Ph.D.
Registration No. 43,371

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990, see p. 32, lines 35-36.

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☐ 7. Other:

RECEIVED

APR 1 0 2002

TECH CENTER 1600/2900

Applicant Must Provide:

☒ An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".

☒ An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
PatentIn Software Program Support (SIRA)
     Technical Assistance..703-287-0200
     To Purchase PatentIn Software........................703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

1632

BIOTECHNOLOGY
SYSTEMS
BRANCH

RAW SEQUENCE LISTING
ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information
Center (STIC) detected errors when processing the following computer readable
form:

Application Serial Number: 09/673,302
Source: OIPE
Date Processed by STIC: 1/16/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:
1) **INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,**
2) **TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY**
FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.
PATENTIN 2.1 e-mail help: **patin21help@uspto.gov** or phone 703-306-4119 (R. Wax)
PATENTIN 3.0 e-mail help: **patin3help@uspto.gov** or phone 703-306-4119 (R. Wax)

TO **REDUCE** ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER VERSION 3.1 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:
        http://www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.
Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom, including:
1. EFS-Bio (**<http://www.uspto.gov/ebc/efs/downloads/documents.htm>** , **EFS Submission User Manual** - ePAVE)
2. U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. **Hand Carry directly to:**
    U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
            Or
    U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. **Federal Express, United Parcel Service, or other delivery service to:** U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

RECEIVED

APR 1 0 ●

TECH CENTER 1600/2900

RECEIVED
JAN 3 1 2002
TECH CENTER 1600/2900

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION	SERIAL NUMBER: 09/673,302

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1 _____ Wrapped Nucleics
     Wrapped Aminos

The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor **after** creating it. Please adjust your right margin to .3; this will prevent "wrapping."

2 _____ Invalid Line Length

The rules require that a line **not exceed** 72 characters in length. This includes white spaces.

3 _____ Misaligned Amino
     Numbering

The numbering under each 5th amino acid is misaligned. Do **not** use tab codes between numbers; use **space characters**, instead.

4 _____ Non-ASCII

The submitted file was **not** saved in ASCII(DOS) text, as **required** by the Sequence Rules. **Please ensure your subsequent submission is saved in ASCII text.**

5 _____ Variable Length

Sequence(s) 2 contain n's or Xaa's representing more than one residue. **Per Sequence Rules, each n or Xaa can only represent a single residue.** Please present the **maximum** number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.

6 _____ PatentIn 2.0
     "bug"

A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. **This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.**

7 _____ Skipped Sequences
     (OLD RULES)

Sequence(s) _____ missing. If intentional, please insert the following lines for **each** skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
(i)   SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to **include** the skipped sequences.

8 _____ Skipped Sequences
     (NEW RULES)

Sequence(s) _____ missing. If **intentional**, please insert the following lines for **each** skipped sequence.
<210> sequence id number
<400> sequence id number
000

9 _____ Use of n's or Xaa's
     (NEW RULES)

Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of **n** or **Xaa**, and which residue n or **Xaa** represents.

10 _____ Invalid <213>
     Response

Per 1.823 of Sequence Rules, the only **valid** <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is **required** when <213> response is Unknown or is Artificial Sequence

11 _____ Use of <220>

Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32)   (Sec. 1.823 of Sequence Rules)

12 _____ PatentIn 2.0
     "bug"

Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

13 _____ Misuse of n

n can only be used to represent a single **nucleotide** in a nucleic acid sequence. N is **not** used to represent any value not specifically a nucleotide.

AMC/MH – Biotechnology Systems Branch – 08/21/2001

OIPE

RAW SEQUENCE LISTING   DATE: 01/16/2002
PATENT APPLICATION: US/09/673,302   TIME: 18:30:22

Input Set : A:\CO5043US.txt
Output Set: N:\CRF3\01162002\I673302.raw

Does Not Comply
Corrected Diskette Needed

```
 3 <110> APPLICANT: COR Therapeutics, Inc.
 4        LAW, Deborah Ann
 5        PHILLIPS, David R.
 7 <120> TITLE OF INVENTION: Transgenic Mammals Expressing Mutant GPIIIa
 9 <130> FILE REFERENCE: 44481-5043-US
11 <140> CURRENT APPLICATION NUMBER: US 09/673,302
12 <141> CURRENT FILING DATE: 2001-03-23
14 <150> PRIOR APPLICATION NUMBER: PCT/US99/08285
15 <151> PRIOR FILING DATE: 1999-04-15
17 <150> PRIOR APPLICATION NUMBER: US 60/115,516
18 <151> PRIOR FILING DATE: 1998-04-15
20 <160> NUMBER OF SEQ ID NOS: 8
22 <170> SOFTWARE: PatentIn version 3.1
24 <210> SEQ ID NO: 1
25 <211> LENGTH: 762
26 <212> TYPE: PRT
27 <213> ORGANISM: Homo sapiens
29 <220> FEATURE:
30 <221> NAME/KEY: misc_feature
31 <223> OTHER INFORMATION: Glycoprotein IIIa
34 <400> SEQUENCE: 1
36 Gly Pro Asn Ile Cys Thr Thr Arg Gly Val Ser Ser Cys Gln Gln Cys
37 1               5                   10                  15
40 Leu Ala Val Ser Pro Met Cys Ala Trp Cys Ser Asp Glu Ala Leu Pro
41              20                  25                  30
44 Leu Gly Ser Pro Arg Cys Asp Leu Lys Glu Asn Leu Leu Lys Asp Asn
45          35                  40                  45
48 Cys Ala Pro Glu Ser Ile Glu Phe Pro Val Ser Glu Ala Arg Val Leu
49      50                  55                  60
52 Glu Asp Arg Pro Leu Ser Asp Lys Gly Ser Gly Asp Ser Ser Gln Val
53 65                  70                  75                  80
56 Thr Gln Val Ser Pro Gln Arg Ile Ala Leu Arg Leu Arg Pro Asp Asp
57              85                  90                  95
60 Ser Lys Asn Phe Ser Ile Gln Val Arg Gln Val Glu Asp Tyr Pro Val
61              100                 105                 110
64 Asp Ile Tyr Tyr Leu Met Asp Leu Ser Tyr Ser Met Lys Asp Asp Leu
65          115                 120                 125
68 Trp Ser Ile Gln Asn Leu Gly Thr Lys Leu Ala Thr Gln Met Arg Lys
69      130                 135                 140
72 Leu Thr Ser Asn Leu Arg Ile Gly Phe Gly Ala Phe Val Asp Lys Pro
73 145                 150                 155                 160
76 Val Ser Pro Tyr Met Tyr Ile Ser Pro Pro Glu Ala Leu Glu Asn Pro
77              165                 170                 175
```

```
 80 Cys Tyr Asp Met Lys Thr Thr Cys Leu Pro Met Phe Gly Tyr Lys His
 81             180             185             190
 84 Val Leu Thr Leu Thr Asp Gln Val Thr Arg Phe Asn Glu Glu Val Lys
 85             195             200             205
 88 Lys Gln Ser Val Ser Arg Asn Arg Asp Ala Pro Glu Gly Gly Phe Asp
 89     210             215             220
 92 Ala Ile Met Gln Ala Thr Val Cys Asp Glu Lys Ile Gly Trp Arg Asn
 93 225             230             235             240
 96 Asp Ala Ser His Leu Leu Val Phe Thr Thr Asp Ala Lys Thr His Ile
 97             245             250             255
100 Ala Leu Asp Gly Arg Leu Ala Gly Ile Val Gln Pro Asn Asp Gly Gln
101             260             265             270
104 Cys His Val Gly Ser Asp Asn His Tyr Ser Ala Ser Thr Thr Met Asp
105             275             280             285
108 Tyr Pro Ser Leu Gly Leu Met Thr Glu Lys Leu Ser Gln Lys Asn Ile
109     290             295             300
112 Asn Leu Ile Phe Ala Val Thr Glu Asn Val Val Asn Leu Tyr Gln Asn
113 305             310             315             320
116 Tyr Ser Glu Leu Ile Pro Gly Thr Thr Val Gly Val Leu Ser Met Asp
117             325             330             335
120 Ser Ser Asn Val Leu Gln Leu Ile Val Asp Ala Tyr Gly Lys Ile Arg
121             340             345             350
124 Ser Lys Val Glu Leu Glu Val Arg Asp Leu Pro Glu Glu Leu Ser Leu
125     355             360             365
128 Ser Phe Asn Ala Thr Cys Leu Asn Asn Glu Val Ile Pro Gly Leu Lys
129     370             375             380
132 Ser Cys Met Gly Leu Lys Ile Gly Asp Thr Val Ser Phe Ser Ile Glu
133 385             390             395             400
136 Ala Lys Val Arg Gly Cys Pro Gln Glu Lys Glu Lys Ser Phe Thr Ile
137             405             410             415
140 Lys Pro Val Gly Phe Lys Asp Ser Leu Ile Val Gln Val Thr Phe Asp
141             420             425             430
144 Cys Asp Cys Ala Cys Gln Ala Gln Ala Glu Pro Asn Ser His Arg Cys
145             435             440             445
148 Asn Asn Gly Asn Gly Thr Phe Glu Cys Gly Val Cys Arg Cys Gly Pro
149     450             455             460
152 Gly Trp Leu Gly Ser Gln Cys Glu Cys Ser Glu Glu Asp Tyr Arg Pro
153 465             470             475             480
156 Ser Gln Gln Asp Glu Cys Ser Pro Arg Glu Gly Gln Pro Val Cys Ser
157             485             490             495
160 Gln Arg Gly Glu Cys Leu Cys Gly Gln Cys Val Cys His Ser Ser Asp
161             500             505             510
164 Phe Gly Lys Ile Thr Gly Lys Tyr Cys Glu Cys Asp Asp Phe Ser Cys
165             515             520             525
168 Val Arg Tyr Lys Gly Glu Met Cys Ser Gly His Gly Gln Cys Ser Cys
169     530             535             540
172 Gly Asp Cys Leu Cys Asp Ser Asp Trp Thr Gly Tyr Tyr Cys Asn Cys
173 545             550             555             560
176 Thr Thr Arg Thr Asp Thr Cys Met Ser Ser Asn Gly Leu Leu Cys Ser
```

RAW SEQUENCE LISTING   DATE: 01/16/2002
PATENT APPLICATION: US/09/673,302   TIME: 18:30:22

Input Set : A:\CO5043US.txt
Output Set: N:\CRF3\01162002\I673302.raw

```
177                   565                 570                 575
180 Gly Arg Gly Lys Cys Glu Cys Gly Ser Cys Val Cys Ile Gln Pro Gly
181             580                 585                 590
184 Ser Tyr Gly Asp Thr Cys Glu Lys Cys Pro Thr Cys Pro Asp Ala Cys
185             595                 600                 605
188 Thr Phe Lys Lys Glu Cys Val Glu Cys Lys Lys Phe Asp Arg Gly Ala
189      610                 615                 620
192 Leu His Asp Glu Asn Thr Cys Asn Arg Tyr Cys Arg Asp Glu Ile Glu
193 625                 630                 635                 640
196 Ser Val Lys Glu Leu Lys Asp Thr Gly Lys Asp Ala Val Asn Cys Thr
197             645                 650                 655
200 Tyr Lys Asn Glu Asp Asp Cys Val Val Arg Phe Gln Tyr Tyr Glu Asp
201             660                 665                 670
204 Ser Ser Gly Lys Ser Ile Leu Tyr Val Val Glu Glu Pro Glu Cys Pro
205             675                 680                 685
208 Lys Gly Pro Asp Ile Leu Val Val Leu Leu Ser Val Met Gly Ala Ile
209      690                 695                 700
212 Leu Leu Ile Gly Leu Ala Ala Leu Leu Ile Trp Lys Leu Leu Ile Thr
213 705                 710                 715                 720
216 Ile His Asp Arg Lys Glu Phe Ala Lys Phe Glu Glu Glu Arg Ala Arg
217             725                 730                 735
220 Ala Lys Trp Asp Thr Ala Asn Asn Pro Leu Tyr Lys Glu Ala Thr Ser
221             740                 745                 750
224 Thr Phe Thr Asn Ile Thr Tyr Arg Gly Thr
225             755                 760
```

228 <210> SEQ ID NO: 2
229 <211> LENGTH: 66
230 <212> TYPE: PRT
231 <213> ORGANISM: Mus musculus
233 <220> FEATURE:
234 <221> NAME/KEY: misc_feature
235 <223> OTHER INFORMATION: Segment of GPIIIa beta-3 subunit
238 <220> FEATURE:
239 <221> NAME/KEY: misc_feature
240 <222> LOCATION: (41)..(66)
241 <223> OTHER INFORMATION: Xaa may be present or missing and may be any variable
244 <400> SEQUENCE: 2

```
246 Lys Leu Leu Leu Thr Thr His Asp Arg Lys Glu Phe Ala Lys Phe Glu
247 1               5                 10                  15
250 Glu Glu Arg Ala Arg Ala Lys Trp Asp Thr Ala Asn Asn Pro Leu Tyr
251             20                  25                  30
254 Lys Glu Ala Thr Ser Thr Phe Thr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
255             35                  40                  45
258 Asn Ile Thr Tyr Arg Gly Thr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
259      50                  55                  60
262 Xaa Xaa
263 65
```

266 <210> SEQ ID NO: 3
267 <211> LENGTH: 66

W--> 254
W--> 262

[handwritten annotations in right and left margins: "see item 5 on Error Summary Sheet", "amino acid variable length is invalid", bracketed "variable"]

```
268 <212> TYPE: PRT
269 <213> ORGANISM: Mus musculus
271 <220> FEATURE:
272 <221> NAME/KEY: misc_feature
273 <223> OTHER INFORMATION: Segment of GPIIIa beta-6 subunit
276 <220> FEATURE:
277 <221> NAME/KEY: misc_feature
278 <222> LOCATION: (41)..(48)
279 <223> OTHER INFORMATION: Xaa may be present or missing and may be any (variable)
282 <400> SEQUENCE: 3
284 Lys Leu Leu Val Ser Phe His Asp Arg Lys Glu Val Ala Lys Phe Glu
285 1               5                   10                  15
288 Ala Glu Arg Ser Lys Ala Lys Trp Gln Thr Gly Thr Asn Pro Leu Tyr
289             20                  25                  30
W--> 292 Arg Gly Ser Thr Ser Thr Phe Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
293             35                  40                  45
296 Asn Val Thr Tyr Lys His Arg Glu Lys Gln Lys Val Asp Leu Ser Thr
297     50                  55                  60
300 Asp Cys
301 65
304 <210> SEQ ID NO: 4
305 <211> LENGTH: 66
306 <212> TYPE: PRT
307 <213> ORGANISM: Mus musculus
309 <220> FEATURE:
310 <221> NAME/KEY: misc_feature
311 <223> OTHER INFORMATION: Segment of GPIIIa beta-1 subunit
314 <220> FEATURE:
315 <221> NAME/KEY: misc_feature
316 <222> LOCATION: (41)..(66)
317 <223> OTHER INFORMATION: Xaa may be present of missing and may be any (variable)
320 <400> SEQUENCE: 4
322 Lys Leu Leu Met Leu Ile His Asp Arg Arg Glu Glu Ala Lys Glu Glu
323 1               5                   10                  15
326 Lys Glu Lys Met Asn Ala Lys Trp Asp Thr Gly Glu Asn Pro Ile Tyr
327             20                  25                  30
W--> 330 Lys Ser Ala Val Thr Thr Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
331             35                  40                  45
W--> 334 Asn Pro Lys Tyr Glu Gly Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
335     50                  55                  60
W--> 338 Xaa Xaa
339 65
342 <210> SEQ ID NO: 5
343 <211> LENGTH: 66
344 <212> TYPE: PRT
345 <213> ORGANISM: Mus musculus
347 <220> FEATURE:
348 <221> NAME/KEY: misc_feature
349 <223> OTHER INFORMATION: Segment of GPIIIa beta-5 subunit
```

```
                    RAW SEQUENCE LISTING              DATE: 01/16/2002
                    PATENT APPLICATION:  US/09/673,302    TIME: 18:30:22

                    Input Set : A:\CO5043US.txt
                    Output Set: N:\CRF3\01162002\I673302.raw

      352 <220> FEATURE:
      353 <221> NAME/KEY: misc_feature
      354 <222> LOCATION: (58)..(66)
      355 <223> OTHER INFORMATION: Xaa may be present or missing and may be any (variable)
      358 <400> SEQUENCE: 5
      360 Lys Leu Leu Val Thr Ile His Asp Arg Arg Glu Phe Ala Lys Phe Gln
      361 1               5                   10                  15
      364 Ser Glu Arg Ser Arg Ala Arg Tyr Glu Met Ala Ser Asn Pro Leu Tyr
      365             20                  25                  30
      368 Arg Lys Pro Ile Ser Thr His Thr Val Asp Phe Thr Phe Asn Lys Phe
      369         35                  40                  45
W-->  372 Asn Lys Ser Tyr Asn Gly Thr Val Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      373     50                  55                  60
W-->  376 Xaa Xaa
      377 65
      380 <210> SEQ ID NO: 6
      381 <211> LENGTH: 66
      382 <212> TYPE: PRT
      383 <213> ORGANISM: Mus musculus
      385 <220> FEATURE:
      386 <221> NAME/KEY: misc_feature
      387 <223> OTHER INFORMATION: Segment of GPIIIa beta-2 subunit
      390 <220> FEATURE:
      391 <221> NAME/KEY: misc_feature
      392 <222> LOCATION: (28)..(66)
      393 <223> OTHER INFORMATION: Xaa may be present or missing and may be any (variable)
      396 <400> SEQUENCE: 6
      398 Lys Ala Leu Thr His Leu Ser Asp Leu Arg Glu Tyr Arg Arg Phe Glu
      399 1               5                   10                  15
W-->  402 Lys Glu Lys Leu Lys Ser Gln Trp Asn Asn Asp Xaa Asn Pro Leu Phe
      403             20                  25                  30
W-->  406 Lys Ser Ala Thr Thr Thr Val Met Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      407         35                  40                  45
W-->  410 Asn Pro Lys Phe Ala Glu Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      411     50                  55                  60
W-->  414 Xaa Xaa
      415 65
      418 <210> SEQ ID NO: 7
      419 <211> LENGTH: 66
      420 <212> TYPE: PRT
      421 <213> ORGANISM: Mus musculus
      423 <220> FEATURE:
      424 <221> NAME/KEY: misc_feature
      425 <223> OTHER INFORMATION: Segment of GPIIIa beta-7 subunit
      428 <220> FEATURE:
      429 <221> NAME/KEY: misc_feature
      430 <222> LOCATION: (41)..(66)
      431 <223> OTHER INFORMATION: Xaa may be present or missing and may be any (variable)
      434 <400> SEQUENCE: 7
```

Use of n and/or Xaa has been detected in the Sequence Listing.
Review the Sequence Listing; ensure a corresponding
information is presented in the <220> to <223> fields of
each sequence using n or Xaa.

FYI →

Please correct this error in Seq. 8, if shown 1/16/02

VERIFICATION SUMMARY   DATE: 01/16/2002
PATENT APPLICATION: US/09/673,302   TIME: 18:30:23

        Input Set : A:\CO5043US.txt
        Output Set: N:\CRF3\01162002\I673302.raw

```
L:254 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:258 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:262 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:292 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:330 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:334 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:338 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:372 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:376 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:402 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:406 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:410 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:414 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:444 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:448 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:452 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:472 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:476 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:480 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:484 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:488 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
```